MX9700036A - Combination therapy for hiv infection. - Google Patents
Combination therapy for hiv infection.Info
- Publication number
- MX9700036A MX9700036A MX9700036A MX9700036A MX9700036A MX 9700036 A MX9700036 A MX 9700036A MX 9700036 A MX9700036 A MX 9700036A MX 9700036 A MX9700036 A MX 9700036A MX 9700036 A MX9700036 A MX 9700036A
- Authority
- MX
- Mexico
- Prior art keywords
- hiv
- combination therapy
- hiv infection
- combination
- infection
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- 208000030507 AIDS Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108010010369 HIV Protease Proteins 0.000 abstract 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 abstract 1
- 229940122440 HIV protease inhibitor Drugs 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 239000004030 hiv protease inhibitor Substances 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 abstract 1
- 229960000689 nevirapine Drugs 0.000 abstract 1
- 229940042443 other antivirals in atc Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The combination of the HIV protease inhibitor Compound J and one or more of nevarapine or an 'alpha'-APA derivative is useful in theinhibition of HIV protease, the inhibition of HIV reverse transcriptase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26708594A | 1994-06-27 | 1994-06-27 | |
| PCT/US1995/007690 WO1996000068A2 (en) | 1994-06-27 | 1995-06-23 | Combination therapy for hiv infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9700036A true MX9700036A (en) | 1997-04-30 |
Family
ID=23017251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9700036A MX9700036A (en) | 1994-06-27 | 1995-06-23 | Combination therapy for hiv infection. |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0767664A2 (en) |
| JP (1) | JPH10503178A (en) |
| AU (1) | AU2863895A (en) |
| CA (1) | CA2193221A1 (en) |
| CZ (1) | CZ375196A3 (en) |
| FI (1) | FI965196A (en) |
| HU (1) | HUT76546A (en) |
| IL (1) | IL114208A0 (en) |
| MX (1) | MX9700036A (en) |
| NO (1) | NO965591L (en) |
| PL (1) | PL317876A1 (en) |
| SK (1) | SK163996A3 (en) |
| WO (1) | WO1996000068A2 (en) |
| ZA (1) | ZA955269B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6689761B1 (en) | 1995-02-01 | 2004-02-10 | Merck & Co., Inc. | Combination therapy for HIV infection |
| US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| EP0872233A1 (en) * | 1997-04-14 | 1998-10-21 | Janssen Pharmaceutica N.V. | Antiretroviral compositions with improved bioavailability |
| GB2324242A (en) * | 1997-04-18 | 1998-10-21 | Atindra Nath Chakrabarty | Medicaments for treating viral infections |
| EE04991B1 (en) | 1999-09-24 | 2008-04-15 | Janssen Pharmaceutica N.V. | Particle, pharmaceutical form, methods of preparation, use of particles and pharmaceutical packaging |
| WO2017051149A1 (en) | 2015-09-23 | 2017-03-30 | Malvern Instruments Limited | Particle characterisation |
-
1995
- 1995-06-19 IL IL11420895A patent/IL114208A0/en unknown
- 1995-06-23 WO PCT/US1995/007690 patent/WO1996000068A2/en not_active Application Discontinuation
- 1995-06-23 JP JP8503245A patent/JPH10503178A/en active Pending
- 1995-06-23 PL PL95317876A patent/PL317876A1/en unknown
- 1995-06-23 SK SK1639-96A patent/SK163996A3/en unknown
- 1995-06-23 MX MX9700036A patent/MX9700036A/en unknown
- 1995-06-23 CZ CZ963751A patent/CZ375196A3/en unknown
- 1995-06-23 HU HU9603567A patent/HUT76546A/en unknown
- 1995-06-23 AU AU28638/95A patent/AU2863895A/en not_active Withdrawn
- 1995-06-23 CA CA002193221A patent/CA2193221A1/en not_active Abandoned
- 1995-06-23 EP EP95923935A patent/EP0767664A2/en not_active Withdrawn
- 1995-06-26 ZA ZA955269A patent/ZA955269B/en unknown
-
1996
- 1996-12-23 FI FI965196A patent/FI965196A/en not_active Application Discontinuation
- 1996-12-27 NO NO965591A patent/NO965591L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA955269B (en) | 1996-02-02 |
| CA2193221A1 (en) | 1996-01-04 |
| JPH10503178A (en) | 1998-03-24 |
| PL317876A1 (en) | 1997-04-28 |
| HUT76546A (en) | 1997-09-29 |
| WO1996000068A3 (en) | 1996-02-22 |
| SK163996A3 (en) | 1997-08-06 |
| FI965196A0 (en) | 1996-12-23 |
| WO1996000068A2 (en) | 1996-01-04 |
| EP0767664A2 (en) | 1997-04-16 |
| NO965591D0 (en) | 1996-12-27 |
| CZ375196A3 (en) | 1997-07-16 |
| IL114208A0 (en) | 1995-10-31 |
| FI965196A (en) | 1996-12-23 |
| NO965591L (en) | 1996-12-27 |
| HU9603567D0 (en) | 1997-02-28 |
| AU2863895A (en) | 1996-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2725392A (en) | Hiv protease inhibitors | |
| MY109834A (en) | Benzoxazinones as inhibitors of hiv reverse transcriptase | |
| DE60036961D1 (en) | GAMMA-HYDROXY-2- (FLUORALKYLAMINOCARBONYL) -1-PIPERAZINE PENTANAMIDE AS AN HIV PROTEASE INHIBITOR | |
| EP0766674A4 (en) | New hiv protease inhibitors | |
| HU9601649D0 (en) | Hiv protease inhibitors | |
| MX9705916A (en) | Combination therapy for hiv infection using the hiv protease inhibitor indinavir adn the reverse transcriptase inhibitor 3tc, optionally together with azt, ddi or ddc. | |
| MX9700036A (en) | Combination therapy for hiv infection. | |
| IL114808A0 (en) | Combination therapy for hiv |